The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline

The establishment of dedicated comprehensive treatment centres more than a half century ago transformed the management of haemophilia in the United States. Formerly, a disease associated with crippling disability and premature death, today, persons with haemophilia who are treated appropriately from infancy and do not develop inhibitors can expect a normal life expectancy and relatively few bleeding episodes. The evolution of the comprehensive haemophilia care, while chastened by the viral epidemics of the 1980s, has been marked by ongoing advances, including prophylaxis, immune tolerance induction, new drugs and gene therapy research. Current challenges include sustaining the comprehensive care model despite decreased funding and expanding the delivery and affordability of comprehensive haemophilia care.

[1]  P. Monahan.  Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors. , 2015, Hematology. American Society of Hematology. Education Program.

[2]  Miguel Ángel Martínez,et al.  Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study , 2015 .

[3]  Benjamin Gardner Sood,et al.  Discrete choice experiment , 2015 .

[4]  L. Valentino,et al.  US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  J. Mahlangu,et al.  Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II) , 2015, Journal of thrombosis and haemostasis : JTH.

[6]  Björn W. Schuller,et al.  Introduction , 2015, Comput. Speech Lang..

[7]  J. Epstein,et al.  Prophylaxis with anti‐inhibitor coagulant complex improves health‐related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  M. Carcao.  Changing paradigm of prophylaxis with longer acting factor concentrates , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  T. Lambert,et al.  The European Haemophilia Network (EUHANET). , 2014, Blood transfusion = Trasfusione del sangue.

[10]  S. Antunes,et al.  Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  P. Cortesi,et al.  Health‐related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti‐inhibitor complex concentrate: results from the Pro‐FEIBA study , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  F. Peyvandi,et al.  Future of coagulation factor replacement therapy , 2013, Journal of thrombosis and haemostasis : JTH.

[13]  C. Winkler,et al.  The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. , 2013, Blood.

[14]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  J. Stockman.  Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors , 2013 .

[16]  Giel Nijpels,et al.  Comprehensive care programs for patients with multiple chronic conditions: a systematic literature review. , 2012, Health policy.

[17]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[18]  C. Kessler,et al.  Healthcare expenditures for males with haemophilia and employer‐sponsored insurance in the United States, 2008 , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  C. Hay,et al.  The principal results of the International Immune Tolerance Study: a randomized dose comparison. , 2012, Blood.

[20]  Mark P Smith,et al.  Immune Tolerance Therapy for Haemophilia , 2000, Drugs.

[21]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[22]  K. High,et al.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges , 2011, Nature Reviews Genetics.

[23]  F. Rosendaal,et al.  Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  G. White.  Hemophilia: an amazing 35-year journey from the depths of HIV to the threshold of cure. , 2010, Transactions of the American Clinical and Climatological Association.

[25]  C. Kessler,et al.  Emerging clinical concerns in the ageing haemophilia patient , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  P. Mannucci,et al.  Back to the future: a recent history of haemophilia treatment , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  G. Auerswald,et al.  Secondary prophylaxis with recombinant activated factor VII improves health‐related quality of life of haemophilia patients with inhibitors , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[28]  B. Konkle,et al.  Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors , 2007, Journal of thrombosis and haemostasis : JTH.

[29]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[30]  S. Darby,et al.  Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. , 2007, Blood.

[31]  E. Santagostino,et al.  International workshop on immune tolerance induction: consensus recommendations 1 , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[32]  P. Babyn,et al.  Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study , 2006, Journal of thrombosis and haemostasis : JTH.

[33]  B. Evatt.  The natural evolution of haemophilia care: developing and sustaining comprehensive care globally , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[34]  L. Mantovani,et al.  Differences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experiment , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[35]  B. Riske,et al.  A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. , 2005, American journal of public health.

[36]  Roshni Kulkarni,et al.  Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. , 2004, Blood.

[37]  C. Lee.  AIDS, hepatitis and hemophilia , 2004, Journal of thrombosis and haemostasis : JTH.

[38]  D. Globe,et al.  Utilization of care in haemophilia: a resource‐based method for cost analysis from the Haemophilia Utilization Group Study (HUGS) , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[39]  C. Kasper.  DIAGNOSIS AND MANAGEMENT OF INHIBITORS TO FACTORS VIII AND IX An Introductory Discussion for Physicians , 2004 .

[40]  B. Riske,et al.  Advances in care of children with hemophilia. , 2003, Seminars in thrombosis and hemostasis.

[41]  W. Hoots.  Comprehensive care for hemophilia and related inherited bleeding disorders: why it matters. , 2003, Current hematology reports.

[42]  B. Lindgren,et al.  On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[43]  D. Grobbee,et al.  Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[44]  D. Lillicrap,et al.  Recombinant Factor IX Recovery and Inhibitor Safety: A Canadian Post-licensure Surveillance Study , 2002, Thrombosis and Haemostasis.

[45]  J. Katz,et al.  The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors , 2002, Thrombosis and Haemostasis.

[46]  F. Beek,et al.  Long‐term outcome of individualized prophylactic treatment of children with severe haemophilia , 2001, British journal of haematology.

[47]  C. Sabin,et al.  The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985 , 2000, Gut.

[48]  L. Aledort.  Economics of Hemophilia Care , 2000, Pathophysiology of Haemostasis and Thrombosis.

[49]  L. Cowan,et al.  Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. , 2000, Blood.

[50]  Mark Brooker,et al.  The world federation of hemophilia , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[51]  E. Tabor.  The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1 , 1999, Transfusion.

[52]  G. Mariani,et al.  International Immune Tolerance Registry, 1997 Update , 1999, Vox Sanguinis.

[53]  Leissinger.  Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[54]  C. Ludlam.  Treatment of haemophilia. , 1998, British journal of haematology.

[55]  H. Pettersson,et al.  Haemophilia prophylaxis in young patients–a long‐term follow‐up , 1997, Journal of internal medicine.

[56]  D. Drotar,et al.  Correlates of psychological distress among mothers of children and adolescents with hemophilia and HIV infection. , 1997, Journal of pediatric psychology.

[57]  F. Rosendaal,et al.  The natural history of chronic hepatitis C in haemophiliacs , 1996, British journal of haematology.

[58]  L. Aledort.  Hemophilia: yesterday, today, and tomorrow. , 1996, The Mount Sinai journal of medicine, New York.

[59]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[60]  J J Goedert,et al.  HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. , 1994, Journal of acquired immune deficiency syndromes.

[61]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[62]  P. Mannucci,et al.  Hemophilia in the 1990s: principles of management and improved access to care. , 1992, Seminars in thrombosis and hemostasis.

[63]  M. Hilgartner,et al.  A consortium for purchase of blood products directed by physicians. , 1988, Annals of internal medicine.

[64]  P. Levine,et al.  The benefits of comprehensive care of hemophilia: a five-year study of outcomes. , 1984, American journal of public health.

[65]  Update on acquired immune deficiency syndrome (AIDS) among patients with hemophilia A. , 1983, Connecticut medicine.

[66]  L. Aledort.  Current concepts in diagnosis and management of hemophilia. , 1982, Hospital practice.

[67]  E. Forman,et al.  Socioeconomic evaluation of a state-funded comprehensive hemophilia-care program. , 1982, The New England journal of medicine.

[68]  L. Aledort.  Lessons from hemophilia. , 1982, The New England journal of medicine.

[69]  L. Aledort.  Methods of care, products available, complications of therapy. , 1977, The Mount Sinai journal of medicine, New York.

[70]  S. Evensen.  [Home transfusion for patients with hemophilia]. , 1976, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[71]  C. Koop.  The National Hemophilia Foundation , 1971, Clinical pediatrics.

[72]  F. Rosner.  Hemophilia in the Talmud and rabbinic writings. , 1969, Annals of internal medicine.

[73]  Å. Ahlberg.  Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. , 1965, Acta orthopaedica Scandinavica. Supplementum.

[74]  E. Hershgold,et al.  High-potency Antihæmophilic Factor Concentrate prepared from Cryoglobulin Precipitate , 1964, Nature.

[75]  J. Oncley,et al.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. II. ELECTROPHORETIC AND ULTRACENTRIFUGAL STUDIES OF SOLUTIONS OF HUMAN SERUM ALBUMIN AND IMMUNE SERUM GLOBULINS. , 1944, The Journal of clinical investigation.